Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2007 Aug;78(8):905–906. doi: 10.1136/jnnp.2006.104695

Heterogeneity in male to female risk for Parkinson's disease

K S M Taylor 1,2,3, J A Cook 1,2,3, C E Counsell 1,2,3
PMCID: PMC2117744  PMID: 17635983

We read with interest the recent meta‐analysis of seven studies that reported that the age‐adjusted incidence of Parkinson's disease was 1.5 times greater in men than in women.1 However, this meta‐analysis excluded several informative studies (such as those with <50 patients and those restricted to older cohorts) and did not explore heterogeneity in the male to female (M:F) ratios. We were also unable to replicate some of the data used in the meta‐analysis. For example, we believe it misquoted some crude incidence rates as being age‐adjusted (eg, the studies from Ferrara and Olmstead County).

In the process of updating our previous systematic review of studies on the incidence of Parkinson's disease,2 we performed a new meta‐analysis of age‐adjusted M:F incidence ratios for Parkinson's disease and attempted to identify the causes of heterogeneity. Additional studies published between January 2002 and April 2005 were identified using the same search strategy and inclusion criteria as those in the previous review.2 Where possible, the age‐standardised M:F incidence ratio for each study was calculated with the Confidence Interval Analysis software V.1 by applying the age‐specific female incidence rates to the corresponding male population. In three studies, an age‐adjusted M:F relative risk (RR) given in the original publication was used instead.

Meta‐analysis of the natural logarithm of age‐standardised M:F ratio (logSR) estimates was performed using a DerSimonian and Laird random effects model. Heterogeneity was formally assessed using the I2 statistic and explored using retrospective meta‐regression analyses, which assessed the influence of study location (dichotomised Western v Asian) and the mean age of onset in the incident parkinsonian cohort (mean age of onset/diagnosis <70 years of age v onset diagnosis ⩾70 years of age). Additionally, we assessed publication bias with a funnel plot of the logSR. The influence of individual studies was assessed by omitting each study one‐by‐one and recalculating the pooled estimates. All meta‐analyses were carried out using STATA V.8 software.

In all, 17 relevant studies including more than 2500 people with Parkinson's disease were identified (table 1). No evidence of publication bias was found. The pooled estimate for the age‐standardised M:F ratio was 1.46 (95% confidence interval (CI) 1.24 to 1.72, p<0.001), but there was a high level of heterogeneity (I2 = 85%). Removal of individual studies altered the pooled estimate only marginally (between 1.42 and 1.51), with the 95% CIs all comfortably excluding the null value. Meta‐regression analysis showed that studies from the West gave significantly greater M:F ratios than those from Asia (table 1; RR from meta‐regression 1.58, 95% CI 1.12 to 2.22, p = 0.009) and that studies in which the mean age of subjects with Parkinson's disease was ⩾70 years (pooled M:F ratio 1.67) gave significantly greater M:F ratios than those with a mean age <70 years (pooled M:F ratio 1.23, RR from meta‐regression 1.38, 95% CI 1.06 to 1.81, p = 0.018). However, heterogeneity remained high within the <70 and ⩾70 years age subgroups (I2 = 80% for both) and for the Western studies subgroup (I2 = 84%).

Table 1 Sex differences in the incidence of Parkinson's disease.

Study location Year Population Number of cases Mean age of onset (years) Age‐standardised M:F ratio (95% CI)
Age (years) Size
Western populations
Southwest Finland2 1976 All 402 988 179 61.6 0.90 (0.50 to 1.50)*
Poznan, Poland2 1989 All 1 308 000 163 66.6† 1.34 (1.06 to 1.67)
Ferrara, Italy2 1991 All 187 381 394 62.6 1.01 (0.86 to 1.17)
Manhattan, USA2 1995 All 213 000 83 76.3 1.53 (1.07 to 2.12)
Navarra, Spain2 1999 All 523 563 86 69.5 2.11 (1.58 to 2.76)
Olmstead, USA2 1999 All 95 000 154 70.8† 2.12 (1.70 to 2.61)
Turku, Finland2 1999 All 196 864 NS 64.8 1.90 (1.40 to 2.60)*
Italy3 2000 65–84 4341 42 76.5† 2.14 (1.43 to 3.07)
Tartu, Estonia4 2003 All 156 417 264 68.8 0.97 (0.75 to 1.26)*
California, USA5 2003 All 4 776 038 person‐years 588 70.5 1.82 (1.63 to 2.02)
Rotterdam, The Netherlands6 2004 ⩾55 6839 67 77.5† 1.34 (0.91 to 1.91)
Central Spain7 2004 ⩾65 5160 30 79.1† 2.39 (1.44 to 3.74)
Cambridge, UK8 2004 All 700 000 201 70.3 1.36 (1.11 to 1.65)
Aberdeen, UK9 2006 All 148 600 50 76.1 2.30 (1.55 to 3.28)
Pooled age‐adjusted M:F ratio 1.57 (1.33 to 1.86)
Asian populations
29 provinces, China2 1991 All 3 869 162 58 69.2† 0.87 (0.55 to 1.32)
Ilan County, Taiwan2 2001 All 75 579 15 67.0† 1.03 (0.45 to 2.04)
Wakayama, Japan10 2002 All 1 080 000 183 73.2† 0.97 (0.76 to 1.21)
Pooled age‐adjusted M:F ratio 0.95 (0.78 to 1.16)
Total pooled age‐adjusted M:F ratio 1.46 (1.24 to 1.72)

M:F, male:female.

*Age‐adjusted RR from original publication.

†Mean age calculated crudely from age‐stratified number of cases.

Our analysis on a larger dataset gave a very similar overall result as that of the previous meta‐analysis,1 with an M:F ratio of 1.46 versus an RR of 1.49. However, there was significant heterogeneity between studies, which was only partly explained by mean age of onset and study location. We found evidence that the M:F difference in the incidence of Parkinson's disease increases with age of onset. Several individual studies have reported similar findings with little difference between the incidence in men and women <60 years of age.5,6,8 The reason for this remains unclear. It may be due to postmenopausal hormonal changes in women or differential exposure of men and women to environmental risk factors in later life.

We also showed that the M:F difference is significantly greater in Western populations than in Asian populations (specifically Chinese or Japanese) where no significant M:F difference was found. Although this subgroup analysis should be interpreted cautiously (as it was based on only three studies), it is supported by findings from an incidence study from California, which also showed no difference in the M:F ratio in an Asian subpopulation.5 This finding argues against a fundamental protective effect of oestrogen, which would be expected to be present in all populations. The fact that the M:F ratio in Asian populations remains different from that in other ethnic groups with regard to those who move to a Western country suggests that there may be genetic influences on the M:F risk of developing Parkinson's disease. However, further high‐quality studies on incidence are required both from Asia and from the West to confirm that these ethnic differences are indeed real.

In summary, therefore, although there is good evidence that men are, in general, about 1.5 times more likely to develop Parkinson's disease than women, this difference is not the same across different studies, and is more pronounced in (and possibly restricted to) people with an older age of onset and in Western populations.

Footnotes

Funding: The Health Services Research Unit is core funded by the Chief Scientist Office of the Scottish Executive Health Department.

Competing interests: None.

References

  • 1.Wooten G F, Currie L J, Bovbjerg V E.et al Are men at greater risk of Parkinson's disease than women? J Neurol Neurosurg Psychiatry 200475637–639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Twelves D, Perkins K, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 20031819–31. [DOI] [PubMed] [Google Scholar]
  • 3.Baldereschi M, Di Carlo A, Rocca W A.et al Parkinson's disease and parkinsonism in a longitudinal study. Two‐fold higher incidence in men. Neurology 2000551358–1363. [DOI] [PubMed] [Google Scholar]
  • 4.Taba P, Asser T. Incidence of Parkinson's disease in Estonia. Neuroepidemiology 20032241–45. [DOI] [PubMed] [Google Scholar]
  • 5.van den Eeden S K, Tanner C M, Bernstein A L.et al Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 20031571015–1022. [DOI] [PubMed] [Google Scholar]
  • 6.de Lau L M L, Giesbergen P C L M, de Rijk M C.et al Incidence of parkinsonism and Parkinson's disease in a general population. The Rotterdam study. Neurology 2004631240–1244. [DOI] [PubMed] [Google Scholar]
  • 7.Benito‐León J, Bermejo‐Pareja F, Morales‐González J M.et al Incidence of Parkinson's disease and parkinsonism in three elderly populations of central Spain. Neurology 200462734–741. [DOI] [PubMed] [Google Scholar]
  • 8.Foltynie T, Brayne C E G, Robbins T W.et al The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004127550–560. [DOI] [PubMed] [Google Scholar]
  • 9.Taylor K S M, Counsell C E, Harris C E.et al Pilot study of the incidence and prognosis of degenerative parkinsonian disorders in Aberdeen, United Kingdom: methods and preliminary results. Mov Disord 200621976–982. [DOI] [PubMed] [Google Scholar]
  • 10.Morioka S, Sakata K, Yoshida S.et al Incidence of Parkinson's disease in Wakayama, Japan. J Epidemiol 200212403–407. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES